Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions

Seeking Alpha / 3 hours from now 1 Views

Allschwil, Switzerland – November 05, 2025
Idorsia Ltd (SIX: IDIA) shares that new analysis of the landmark Phase 3 PRECISION study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented at the American Society of Nephrology (ASN) Kidney Week 2025, taking place in Houston, TX, November 5–9, 2025.

Read more

Comments